Effectiveness of a cytolysin-enriched vaccine for protection of cattle against infectious bovine keratoconjunctivitis

George, Lisle W.; Borrowman, Andrew J.; Angelos, John A.

doi:10.2460/ajvr.2005.66.136

Cited by 20 publications

(4 citation statements)

References 23 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A partially purified M. bovis cytolysin (cytotoxin) adjuvanted with Quil A was effective at reducing IBK in vaccinated calves (George et al 2005). Limitations to large scale production of this partially purified M. bovis cytolysin vaccine prompted further investigations into recombinant M. bovis cytotoxin vaccines.…”

Section: Introductionmentioning

confidence: 99%

Recombinant Moraxella bovoculi cytotoxin-ISCOM matrix adjuvanted vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis

et al. 2010

Self Cite

View full text Add to dashboard Cite

A randomized, blinded, controlled field trial was conducted during summer 2006 in a northern California, USA, herd of beef cattle to evaluate the efficacy of a recombinant Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye). A convenience sample comprised of 127 steers were administered a subcutaneous dose of either adjuvant alone (ISCOM matrices; control group) or recombinant M. bovoculi cytotoxin carboxy terminus adjuvanted with ISCOM matrices (MbvA group) and were boostered 21 days later. The steers were examined once weekly for 15 weeks for evidence of IBK. No significant difference in the cumulative proportion of corneal ulcerations was detected between groups. Compared to the control calves, the MbvA vaccinates had significantly higher increases in serum neutralizing titers to M. bovoculi hemolysin between week 0 and week 6. The prevalence of M. bovis isolations was higher from ulcerated eyes of calves vaccinated with MbvA as compared to control calves. Vaccination of calves against the carboxy terminus of M. bovoculi RTX toxin resulted in significant increases in serum hemolysin neutralizing titers and may modulate organism type cultured from ulcerated eyes of calves in herds where both M. bovis and M. bovoculi exist. Use of M. bovoculi antigens alone in vaccines to prevent IBK may not be beneficial in herds where IBK is associated with both M. bovoculi and M. bovis.

show abstract

Section: Introductionmentioning

confidence: 99%

Recombinant Moraxella bovoculi cytotoxin-ISCOM matrix adjuvanted vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…Beneficial effects attributable to the cytolysin vaccine include a slower rate of IBK onset, lessened clinical disease at first observation, smaller corneal ulcers and fewer calves affected with IBK. 61 Further, a recombinant M bovis cytotoxin-ISCOM (immune stimulating complex) matrix adjuvanted vaccine establishes beneficial trends including longer times to first ulceration, faster healing times and the reduction of the cumulative proportion of naturally occurring IBK. 62 Additional virulence determinants Although type 4 pili and haemolysin are the virulence determinants substantively linked to M bovis pathogenicity, 14,16,19,43,63 in vitro studies have suggested that M bovis produces a number of other possible virulence determinants that include proteases, fibrinolysins and phospholipases.…”

Section: Antigenic Surveillancementioning

confidence: 99%

Infectious bovine keratoconjunctivitis vaccine development

Mcconnel

House

2005

Aust Veterinary J

View full text Add to dashboard Cite

Infectious bovine keratoconjunctivitis is a common and highly contagious ocular disease affecting cattle worldwide. The tremendous economic losses attributable to this disease warrant continued investigation into methods of prevention. Multiple virulence factors have been linked to the primary aetiologic agent, Moraxella bovis. Efforts to develop an efficacious vaccine have primarily focused upon the use of surface pili or cytolysin to stimulate host immunity; however, M. bovis possesses other virulence determinants that include proteases, fibrinolysins, phospholipases and other cell surface components such as outer membrane proteins. These potentially conserved antigens provide additional possibilities for vaccine development. Examination of appropriate antigen presentation is necessary to attain an adequate immune response. Further, the potential for antigenic diversity as well as epitope conversion requires continuous epidemiological surveillance of isolates recovered from outbreaks. Current work targeting conserved immunogens provides hope for efficacious vaccines that when used in tandem with proper management may control, if not prevent, infectious bovine keratoconjunctivitis.

show abstract

“…Multiple studies that have evaluated commercially available or autogenous vaccines against IBK have reported lack of efficacy of these parenterally administered vaccines [24] , [25] , [26] , [27] . An experimental parenteral vaccine that used a partially purified native M. bovis cytotoxin as antigen showed some efficacy against IBK [28] . Other parenterally-administered M. bovis cytotoxin subunit vaccines have also been investigated [29] , [30] .…”

Section: Introductionmentioning

confidence: 99%

Randomized controlled field trial to assess the efficacy of an intranasal Moraxella bovis cytotoxin vaccine against naturally occurring infectious bovine keratoconjunctivitis

Angelos,

Agulto,

Mandzyuk

et al. 2023

Vaccine: X

Self Cite

View full text Add to dashboard Cite

Effectiveness of a cytolysin-enriched vaccine for protection of cattle against infectious bovine keratoconjunctivitis

Abstract: Calves that were vaccinated with a cytolysin-enriched vaccine had some resistance to IBK. Vaccines containing concentrated diafiltered M bovis cytolysin could protect beef calves against IBK.

Cited by 20 publications

References 23 publications

Recombinant Moraxella bovoculi cytotoxin-ISCOM matrix adjuvanted vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis

Recombinant Moraxella bovoculi cytotoxin-ISCOM matrix adjuvanted vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis

Infectious bovine keratoconjunctivitis vaccine development

Randomized controlled field trial to assess the efficacy of an intranasal Moraxella bovis cytotoxin vaccine against naturally occurring infectious bovine keratoconjunctivitis

Contact Info

Product

Resources

About